These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 20577660)

  • 21. A randomized, placebo-controlled, double-blinded, parallel-group, 5-week study of buprenorphine transdermal system in adults with osteoarthritis.
    Munera C; Drehobl M; Sessler NE; Landau C
    J Opioid Manag; 2010; 6(3):193-202. PubMed ID: 20642248
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Transdermal buprenorphine in non-oncological moderate-to-severe chronic pain.
    Gatti A; Dauri M; Leonardis F; Longo G; Marinangeli F; Mammucari M; Sabato AF
    Clin Drug Investig; 2010; 30 Suppl 2():31-8. PubMed ID: 20670047
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Safety of buprenorphine transdermal system in the management of pain in older adults.
    Pergolizzi JV; Raffa RB; Marcum Z; Colucci S; Ripa SR
    Postgrad Med; 2017 Jan; 129(1):92-101. PubMed ID: 27929709
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Controlled-release oxycodone and naloxone in the treatment of chronic low back pain: a placebo-controlled, randomized study.
    Cloutier C; Taliano J; O'Mahony W; Csanadi M; Cohen G; Sutton I; Sinclair D; Awde M; Henein S; Robinson L; Eisenhoffer J; Piraino PS; Harsanyi Z; Michalko KJ
    Pain Res Manag; 2013; 18(2):75-82. PubMed ID: 23662289
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A Subgroup Analysis Found no Diminished Response to Buprenorphine Transdermal System Treatment for Chronic Low Back Pain Patients Classified with Depression.
    Yarlas A; Miller K; Wen W; Lynch SY; Munera C; Dain B; Pergolizzi JV; Raffa R; Ripa SR
    Pain Pract; 2016 Apr; 16(4):473-85. PubMed ID: 25865734
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Once-weekly transdermal buprenorphine application results in sustained and consistent steady-state plasma levels.
    Kapil RP; Cipriano A; Friedman K; Michels G; Shet MS; Colucci SV; Apseloff G; Kitzmiller J; Harris SC
    J Pain Symptom Manage; 2013 Jul; 46(1):65-75. PubMed ID: 23026548
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effectiveness and tolerability of transdermal buprenorphine patches: a multicenter, prospective, open-label study in Asian patients with moderate to severe chronic musculoskeletal pain.
    Yoon DH; Bin SI; Chan SK; Chung CK; In Y; Kim H; Lichauco JJ; Mok CC; Moon YW; Ng TK; Penserga EG; Shin DA; You D; Moon H
    BMC Musculoskelet Disord; 2017 Aug; 18(1):337. PubMed ID: 28778219
    [TBL] [Abstract][Full Text] [Related]  

  • 28. US practitioner prescribing practices and patient characteristics of those newly treated with a buprenorphine transdermal patch system.
    Pergolizzi JV; Ben-Joseph R; Chang CL; Hess G
    Curr Med Res Opin; 2014 Aug; 30(8):1579-87. PubMed ID: 24689806
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A randomized, 14-day, double-blind study evaluating conversion from hydrocodone/acetaminophen (Vicodin) to buprenorphine transdermal system 10 μg/h or 20 μg/h in patients with osteoarthritis pain.
    Ripa SR; McCarberg BH; Munera C; Wen W; Landau CJ
    Expert Opin Pharmacother; 2012 Jun; 13(9):1229-41. PubMed ID: 22409388
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effectiveness and tolerability of the buprenorphine transdermal system in patients with moderate to severe chronic pain: a multicenter, open-label, uncontrolled, prospective, observational clinical study.
    Muriel C; Failde I; Micó JA; Neira M; Sánchez-Magro I
    Clin Ther; 2005 Apr; 27(4):451-62. PubMed ID: 15922818
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A randomized, double-blind, crossover comparison of the efficacy and safety of oral controlled-release tramadol and placebo in patients with painful osteoarthritis.
    Thorne C; Beaulieu AD; Callaghan DJ; O'Mahony WF; Bartlett JM; Knight R; Kraag GR; Akhras R; Piraino PS; Eisenhoffer J; Harsanyi Z; Darke AC
    Pain Res Manag; 2008; 13(2):93-102. PubMed ID: 18443671
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effects of buprenorphine on QT intervals in healthy subjects: results of 2 randomized positive- and placebo-controlled trials.
    Harris SC; Morganroth J; Ripa SR; Thorn MD; Colucci S
    Postgrad Med; 2017 Jan; 129(1):69-80. PubMed ID: 27927048
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Dose-Dependent Flux of Buprenorphine Following Transdermal Administration in Healthy Subjects.
    Wang Y; Cipriano A; Munera C; Harris SC
    J Clin Pharmacol; 2016 Oct; 56(10):1263-71. PubMed ID: 26865472
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Tramadol/acetaminophen combination tablets for the treatment of chronic lower back pain: a multicenter, randomized, double-blind, placebo-controlled outpatient study.
    Ruoff GE; Rosenthal N; Jordan D; Karim R; Kamin M;
    Clin Ther; 2003 Apr; 25(4):1123-41. PubMed ID: 12809961
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Buprenorphine 5, 10 and 20 μg/h transdermal patch: a review of its use in the management of chronic non-malignant pain.
    Plosker GL
    Drugs; 2011 Dec; 71(18):2491-509. PubMed ID: 22141389
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Efficacy and tolerability of buccal buprenorphine in opioid-experienced patients with moderate to severe chronic low back pain: results of a phase 3, enriched enrollment, randomized withdrawal study.
    Gimbel J; Spierings ELH; Katz N; Xiang Q; Tzanis E; Finn A
    Pain; 2016 Nov; 157(11):2517-2526. PubMed ID: 27434505
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Low doses of transdermal buprenorphine in opioid-naive patients with cancer pain: a 4-week, nonrandomized, open-label, uncontrolled observational study.
    Mercadante S; Porzio G; Ferrera P; Aielli F; Verna L; Tirelli W; Villari P; Casuccio A
    Clin Ther; 2009 Oct; 31(10):2134-8. PubMed ID: 19922884
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Oxymorphone extended release for the treatment of chronic low back pain: a retrospective pooled analysis of enriched-enrollment clinical trial data stratified according to age, sex, and prior opioid use.
    Peniston JH; Gould E
    Clin Ther; 2009 Feb; 31(2):347-59. PubMed ID: 19302907
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Tolerability, Safety, and Effectiveness of Oxycodone DETERx in Elderly Patients ≥65 Years of Age with Chronic Low Back Pain: A Randomized Controlled Trial.
    Kopecky EA; Vaughn B; Lagasse S; O'Connor M
    Drugs Aging; 2017 Aug; 34(8):603-613. PubMed ID: 28600725
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Fentanyl buccal tablet (FBT) for relief of breakthrough pain in opioid-treated patients with chronic low back pain: a randomized, placebo-controlled study.
    Portenoy RK; Messina J; Xie F; Peppin J
    Curr Med Res Opin; 2007 Jan; 23(1):223-33. PubMed ID: 17207304
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.